News

• FDA approves generic teriparatide and levetiracetam
• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs

Research

• Japan’s drug shortage crisis: challenges and policy solutions
• Saudi FDA drug approvals and GMP inspections: trend analysis
• Generic medications in the Lebanese community: understanding and public perception
• Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study

General

• Generic drug growth in Brazil and Venezuela
• EMA launches European shortages monitoring platform to tackle persistent medicine shortages
• Market penetration of generic drugs in Mexico and Brazil
• FDA releases one-year progress report for the Generic Drug Cluster

News

• EMA recommends approval for teriparatide biosimilar Zandoriah
• FDA approves third interchangeable ranibizumab biosimilar Nufymco
• FDA approves Poherdy (first interchangeable pertuzumab) and Armlupeg (pegfilgrastim) biosimilars
• EMA recommends approval for insulin glargine biosimilar Ondibta and denosumab biosimilar Osqay

Research

• Reaching ESG goals in pharmaceutical development
• What is the future for the US biosimilar interchangeability designation
• Biosimilar clinical efficacy studies: are they still necessary?
• How the WHO is expanding access to biosimilars

General

• Biosimilars approved in the US
• Samsung Bioepis wins Pyzchiva case; Regeneron patent rulings threaten foreign biosimilars
• Biosimilars approved in Europe
• Biosimilars approved in Australia

• Latin American Forum
• Non‐Biological Complex Drugs
• Country Focus

• Guidelines
• Policies & Legislation
• Reports

• Conferences
• Sponsored Articles
• Sponsored Links